ES2037020T3 - Procedimiento para la obtencion de formas solidas farmaceuticas. - Google Patents

Procedimiento para la obtencion de formas solidas farmaceuticas.

Info

Publication number
ES2037020T3
ES2037020T3 ES198787104724T ES87104724T ES2037020T3 ES 2037020 T3 ES2037020 T3 ES 2037020T3 ES 198787104724 T ES198787104724 T ES 198787104724T ES 87104724 T ES87104724 T ES 87104724T ES 2037020 T3 ES2037020 T3 ES 2037020T3
Authority
ES
Spain
Prior art keywords
procedure
solid pharmaceutical
pharmaceutical forms
obtaining solid
vinylpyrolidon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787104724T
Other languages
English (en)
Inventor
Hans-Helmut Dr. Goertz
Roger Guenther Dr. Klimesch
Klaus Dr. Laemmerhirt
Siegfried Dr. Lang
Axel Dr. Sanner
Reinhard Dr. Spengler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Application granted granted Critical
Publication of ES2037020T3 publication Critical patent/ES2037020T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035Medical or pharmaceutical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

CONSISTE EN LA COMBINACION DE, AL MENOS, UNA SUSTANCIA FARMACEUTICA CON, AL MENOS, UN MEDIO ALEATORIO CONCILIANTE FARMACOLOGICO FUNDIBLE Y, DADO EL CASO OTROS MEDIOS AUXILIARES GALENICOS E INYECTABLES O EXTRUSIONABLES Y MOLDEABLES A TEMPERATURA DE 50 A 180 C, ESTABLECIENDOSE COMO MEDIO ALEATORIO FUNDIBLE UN N-VINILPIRROLIDON POLIMERIZADO QUE CONTIENE, AL MENOS, EL 20% EN PESO DE N-VINILPIRROLIDON POLIMERIZADO Y, DADO EL CASO, UNA SUSTENCIA AGLUTINANTE POLIMERIZADA DE CROMONOMERO Y/O OXIGENO.
ES198787104724T 1986-04-11 1987-03-31 Procedimiento para la obtencion de formas solidas farmaceuticas. Expired - Lifetime ES2037020T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863612212 DE3612212A1 (de) 1986-04-11 1986-04-11 Verfahren zur herstellung von festen pharmazeutischen formen

Publications (1)

Publication Number Publication Date
ES2037020T3 true ES2037020T3 (es) 1993-06-16

Family

ID=6298473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787104724T Expired - Lifetime ES2037020T3 (es) 1986-04-11 1987-03-31 Procedimiento para la obtencion de formas solidas farmaceuticas.

Country Status (20)

Country Link
US (1) US4801460A (es)
EP (1) EP0240904B1 (es)
JP (1) JPH089551B2 (es)
KR (1) KR920003575B1 (es)
CN (1) CN1022666C (es)
AT (1) ATE77739T1 (es)
AU (1) AU587897B2 (es)
CA (1) CA1308353C (es)
CS (1) CS268177B2 (es)
DE (2) DE3612212A1 (es)
ES (1) ES2037020T3 (es)
FI (1) FI87887C (es)
GR (1) GR3005866T3 (es)
HU (1) HU196132B (es)
MD (1) MD374C2 (es)
NO (1) NO170570C (es)
PT (1) PT84661B (es)
SU (1) SU1731037A3 (es)
UA (1) UA13038A1 (es)
YU (1) YU46534B (es)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
CA1334379C (en) * 1987-11-24 1995-02-14 James William Mcginity Method for preparing a solid sustained release form of a functionally active composition
US5051261A (en) * 1987-11-24 1991-09-24 Fmc Corporation Method for preparing a solid sustained release form of a functionally active composition
DE3803482A1 (de) * 1988-02-05 1989-08-17 Lohmann Therapie Syst Lts Schwimmfaehiges orales therapeutisches system
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830355A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur herstellung von pharmazeutischen tabletten
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
US5310549A (en) * 1989-08-31 1994-05-10 Ecolab Inc. Solid concentrate iodine composition
WO1991007184A1 (en) * 1989-11-08 1991-05-30 Gaf Chemicals Corporation SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2?
US5008106A (en) * 1989-12-14 1991-04-16 Gaf Chemicals Corporation Method for reducing the microbial content of surfaces with a microbiocidal, anhydrous complex of PVP-H2 O2
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
FR2663818B1 (fr) 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animale Procede de preparation de granules de principes actifs par extrusion.
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
DK0508756T3 (da) * 1991-04-09 1997-03-24 Takeda Chemical Industries Ltd Stabiliseret vitamin D-præparat
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
HU219332B (hu) 1991-09-06 2001-03-28 Mcneilab Inc Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények
WO1993007859A1 (en) * 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DK0617612T3 (da) 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
US5190749A (en) * 1992-01-13 1993-03-02 Isp Investments Inc. Copolymers of vinyl pyrrolidone and a quaternary ammonium monomer complexed with H2 O2 in the form of free-flowing powders
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
TW246635B (es) * 1992-10-08 1995-05-01 Shell Internat Res Schappej B V
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
WO1995013794A1 (en) * 1993-11-18 1995-05-26 Nippon Shinyaku Co., Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
EP0691124A1 (en) * 1994-07-07 1996-01-10 Sara Lee/DE N.V. Mouth care products
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19509806A1 (de) * 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
DE19509805A1 (de) * 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
DE19511131A1 (de) * 1995-03-27 1996-10-02 Basf Ag Mechanisch stabile feste Wirkstoffzubereitungsformen
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
BE1009375A6 (nl) * 1995-05-29 1997-02-04 Picanol Nv Kanteninrichting voor weefmachines.
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
WO1997008950A1 (en) * 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19602206A1 (de) * 1996-01-23 1997-07-24 Basf Ag Zubereitungen nichtsteroidaler Analgetika
US6090419A (en) * 1996-05-02 2000-07-18 Mccormick & Company, Inc. Salt compositions and method of preparation
DE19629040A1 (de) * 1996-07-19 1998-01-22 Basf Ag Pflanzenextrakthaltige Arzneiformen
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19635676A1 (de) * 1996-09-03 1998-03-05 Basf Ag Feste geschäumte Wirkstoffzubereitungen
HRP970485A2 (en) 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
DE19649565A1 (de) * 1996-11-29 1998-06-04 Knoll Ag Verfahren zum Herstellen von Granulaten eines Wasch- oder Reinigungsmittels
DE19710213A1 (de) * 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19812688A1 (de) 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19814730A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verwendung von N-Vinyllacram oder N-Vinylamin haltigen Copolymeren als Matrix zur Herstellung von festen pharmazeutischen und kosmetischen Darreichungsformen
US6541425B1 (en) 1998-04-30 2003-04-01 Basf Aktiengesellschaft Retarding formulations of active substances used for plant protection
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
DE19840256A1 (de) 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
DE19841244A1 (de) 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
DE19842914A1 (de) 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
DE19843904A1 (de) 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19843903A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit copolymerem Bindemittel
DE19847618A1 (de) 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
WO2000028816A1 (de) * 1998-11-12 2000-05-25 Basf Aktiengesellschaft Pflanzenschutzmitteltabletten
DE19853985A1 (de) * 1998-11-23 2000-05-25 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
IL143761A0 (en) * 1998-12-16 2002-04-21 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
DE19901383A1 (de) 1999-01-15 2000-07-20 Knoll Ag Verfahren zur Herstellung unterschiedlicher fester Dosierungsformen
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
DE19943501A1 (de) 1999-09-10 2001-03-15 Basf Ag Unterwassergranulation wirkstoffhaltiger Schmelzen
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
DE10017102A1 (de) 2000-04-06 2001-10-11 Basf Ag Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
AU2003206382B2 (en) * 2002-01-03 2008-01-24 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
EP1482914B1 (en) * 2002-03-11 2015-04-22 Novartis AG Implantable drug delivery device for the eye
DE10213242A1 (de) * 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
AU2003249474A1 (en) 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
ES2286486T3 (es) * 2002-12-17 2007-12-01 ABBOTT GMBH & CO. KG Formulacion que comprende acido fenofibrico, una sal o un derivado fisiologicamente aceptables del mismo.
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
CN101091695B (zh) * 2003-02-03 2011-01-19 诺瓦提斯公司 药物制剂
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US20040219210A1 (en) * 2003-05-01 2004-11-04 Jian-Hwa Guo Controlled release solid dosage nifedipine formulations
WO2005003192A1 (en) * 2003-06-26 2005-01-13 Symyx Technologies, Inc. Synthesis of photoresist polymers
TW200526274A (en) 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005027864A1 (en) * 2003-09-19 2005-03-31 Symyx Technologies, Inc. Materials for enhanced delivery of hydrophilic active agents in personal care formulations
MXPA06005545A (es) * 2003-11-18 2006-08-17 Boehringer Ingelheim Int Preparacion farmaceutica solida.
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CA2560165A1 (en) * 2004-05-04 2005-11-10 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
WO2005115343A2 (de) 2004-05-28 2005-12-08 Abbott Gmbh & Co. Kg Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
MX2007014068A (es) * 2005-05-10 2008-02-07 Novartis Ag Composiciones farmaceuticas de liberacion modificada de famciclovir.
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
RU2423997C9 (ru) * 2005-07-05 2011-11-20 Эббетт ГмбХ унд Ко. КГ Композиция и лекарственная форма, содержащие твердую или полутвердую матрицу
EP1912626B1 (en) 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Dosage forms with improved bioavailability
JP5538718B2 (ja) 2005-08-08 2014-07-02 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつイトラコナゾール組成物
US7534381B2 (en) * 2005-09-14 2009-05-19 Isp Investments Inc. Process and apparatus for forming agglomerates of a powder composition of an active and binder
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
US20080145405A1 (en) * 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
RU2356539C2 (ru) * 2006-12-28 2009-05-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Твердая лекарственная форма бетагистина дигидрохлорида и способ ее получения
US7607596B1 (en) 2007-03-07 2009-10-27 Exxpharma, LLC Process for enhancing the solubility of poorly soluble drugs
JP2011503048A (ja) 2007-11-08 2011-01-27 グラクソ グループ リミテッド 医薬製剤
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
WO2009150228A2 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
BR122021018683B1 (pt) * 2008-10-07 2022-11-16 Kudos Pharmaceuticals Limited Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida
US9789065B2 (en) 2008-10-07 2017-10-17 Basf Se Process for producing oral dosage forms with controlled release
CN102573755A (zh) * 2009-09-18 2012-07-11 巴斯夫欧洲公司 制备具有低水溶性的物质的制剂的方法
WO2011101352A2 (en) 2010-02-18 2011-08-25 Abbott Gmbh & Co. Kg Test solvent for evaluating the compatibility of biologically active substances and graft copolymers
EP2463327A3 (de) 2010-12-10 2015-06-03 Basf Se Verfahren zur herstellung von granulaten, enthaltend mindestens eine wasserlösliche komponente
CN103260609B (zh) 2010-12-23 2017-08-11 雅培股份有限两合公司 基于固体分散体的固体延缓制剂
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
CN104666084B (zh) * 2014-11-27 2018-07-13 天津坤健生物制药有限公司 一种提高缓控释包衣片溶出度稳定性的方法
MD4399C1 (ro) * 2015-02-19 2016-09-30 Государственный Университет Молд0 Material polimeric cu proprietăţi antibacteriene
CN107920998B (zh) * 2015-08-21 2021-07-27 巴斯夫欧洲公司 基于n-乙烯基吡咯烷酮和丙烯酸的水溶性聚合物作为药物助剂的用途
EP3337459A1 (de) * 2015-08-21 2018-06-27 Basf Se Salze von wirkstoffen mit polymeren gegenionen
BR112019005774B1 (pt) 2016-09-27 2022-10-11 L.P. Brown Company, Inc Folhas de material de embalagem de fardos colhidos
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
DE1137009B (de) * 1961-01-04 1962-09-27 Bayer Ag Verfahren zur Herstellung eines leichtloeslichen Streptomycinsalzes
NL297357A (es) * 1962-08-31
GB1348786A (en) * 1971-05-14 1974-03-20 Plessey Co Ltd Apparatus and methods for assessing the length of a moving vehicle
GB1388786A (en) * 1972-04-03 1975-03-26 Scherer Corp R P Integral solid gel-lattice dosage form of high-moisture content
CA1211892A (en) * 1982-09-20 1986-09-23 James R. Cho Preparation of polyvinylpyrrolidone or vinylpyrrolidone/vinyl acetate copolymers of various molecular weights using a single initiator system
FI82188C (fi) * 1983-03-16 1991-02-11 Boehringer Ingelheim Ltd Foerfarande foer framstaellning av en vattenloeslig, farmaceutiskt godtagbar dispersion av klortalidon.
DE3312668A1 (de) * 1983-04-08 1984-10-11 Basf Ag, 6700 Ludwigshafen Wasserloesliche polymere mit geringer hygroskopie
US4661521A (en) * 1984-04-30 1987-04-28 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone

Also Published As

Publication number Publication date
SU1731037A3 (ru) 1992-04-30
YU46534B (sh) 1993-11-16
YU59187A (en) 1988-08-31
EP0240904A3 (en) 1988-11-30
NO871513D0 (no) 1987-04-10
EP0240904A2 (de) 1987-10-14
CN87103409A (zh) 1987-12-09
AU7141387A (en) 1987-10-15
DE3612212A1 (de) 1987-10-15
HU196132B (en) 1988-10-28
UA13038A1 (uk) 1997-02-28
FI871539A0 (fi) 1987-04-08
MD374C2 (ro) 1996-05-31
JPS62242630A (ja) 1987-10-23
CS268177B2 (en) 1990-03-14
CA1308353C (en) 1992-10-06
JPH089551B2 (ja) 1996-01-31
KR920003575B1 (ko) 1992-05-04
NO170570C (no) 1992-11-04
HUT43958A (en) 1988-01-28
ATE77739T1 (de) 1992-07-15
AU587897B2 (en) 1989-08-31
FI87887C (fi) 1993-03-10
CS253287A2 (en) 1989-04-14
PT84661B (pt) 1989-11-30
GR3005866T3 (es) 1993-06-07
NO170570B (no) 1992-07-27
KR870009715A (ko) 1987-11-30
FI87887B (fi) 1992-11-30
PT84661A (en) 1987-05-01
DE3780059D1 (de) 1992-08-06
FI871539L (fi) 1987-10-12
CN1022666C (zh) 1993-11-10
EP0240904B1 (de) 1992-07-01
NO871513L (no) 1987-10-12
US4801460A (en) 1989-01-31

Similar Documents

Publication Publication Date Title
DK138590D0 (da) Middel til transdermal applikation indeholdende gestoden
FR2710063B1 (fr) 3-Aryl-benzofurannones, utilisées en tant que stabilisants, compositions les contenant, et leur utilisation.
ES2039488T3 (es) Procedimiento para la preparacion de 1,1,1-trifluoro-2,2-dicloroetano mediante hidrofluoracion en presencia de catalizadores.
DE3669315D1 (de) Phenoxyalkylaminopyrimidinderivate, deren herstellung und diese enthaltende insektizide und akarizide zusammensetzungen.
DE3586545D1 (de) Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
DE68901417D1 (de) Pharmazeutische zusammensetzung.
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
DE3860503D1 (de) 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung.
DE69714253D1 (de) Stickstoffoxydabgebendes präparat zur reduzierung der toxizität von wirkstoffen
MX9203725A (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirrizinato como aumentador de absorcion.
ES2044662T3 (es) Catalizadores de platino sobre soporte de grafito y su empleo.
DE68909958D1 (de) Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung.
ES2195573T3 (es) Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion.
MX9401211A (es) Composicion y procedimiento para combatir la aglomeracion de abonos.
ES2131612T3 (es) Oligomeros de union a acidos nucleicos con ramificacion en c para terapia y diagnostico.
NL190585B (nl) Polymeersamenstelling, ten gebruike in de vorm van een vel of laminaat in de landbouw.
NL175882B (nl) Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
FI811832A7 (fi) Modifioidut glukosaminoglykaanit, joilla on antilipeeminen vaikutus ja joilta olennaisesti puuttuu koaguloitumikoaguloitumisen estovaikutus.
ES2082852T3 (es) Composicion liquida de prostaglandina.
ES2132300T3 (es) Lamina de polipropileno, orientada biaxialmente, con contenido de resina, el procedimiento para su fabricacion y su uso.
ES2032922T5 (es) Empleo de los antagonicos de parf-aceter para la fabricacion de un medicamento para la prevencion de arteriosclerosis.
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
DE3873011D1 (de) Pharmazeutische zusammensetzung, enthaltend piperidinalkanolderivate.
ES507686A0 (es) Procedimiento para reducir el contenido residual total de epihalohidrina y 1,3-dihalo-2-propanol combinados.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 240904

Country of ref document: ES